Abstract
The excessive contraction of small arteries under high blood pressure is the main contributor to the pathological change of hypertension. Current anti-hypertensive drugs, which lack a selective effect on small arteries in a hypertensive state, may cause many adverse effects. We have developed a novel opener of ATP-sensitive potassium channels, iptakalim, the vasorelaxing action of which is determined by the hypertensive status of small arteries. In conscious strokeprone, spontaneously hypertensive rats and “two-kidneys, one-clip” renal hypertensive dogs, this compound produced long-lasting hypotensive effects, with no tolerance. Furthermore, it exerted a protective effect against hypertensive damage to target organs. Given its potency and fewer side effects, iptakalim hydrochloride is a promising drug for the treatment of hypertension.
Keywords: hypertension, atp-sensitive potassium channel, iptakalim, small artery, vasodilator, side effects, selective hypotensive efficacy, cardiovascular remodeling
Current Vascular Pharmacology
Title: Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers
Volume: 3 Issue: 2
Author(s): Hai Wang, Ying-Li Zhang and Yu-Ping Chen
Affiliation:
Keywords: hypertension, atp-sensitive potassium channel, iptakalim, small artery, vasodilator, side effects, selective hypotensive efficacy, cardiovascular remodeling
Abstract: The excessive contraction of small arteries under high blood pressure is the main contributor to the pathological change of hypertension. Current anti-hypertensive drugs, which lack a selective effect on small arteries in a hypertensive state, may cause many adverse effects. We have developed a novel opener of ATP-sensitive potassium channels, iptakalim, the vasorelaxing action of which is determined by the hypertensive status of small arteries. In conscious strokeprone, spontaneously hypertensive rats and “two-kidneys, one-clip” renal hypertensive dogs, this compound produced long-lasting hypotensive effects, with no tolerance. Furthermore, it exerted a protective effect against hypertensive damage to target organs. Given its potency and fewer side effects, iptakalim hydrochloride is a promising drug for the treatment of hypertension.
Export Options
About this article
Cite this article as:
Wang Hai, Zhang Ying-Li and Chen Yu-Ping, Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers, Current Vascular Pharmacology 2005; 3 (2) . https://dx.doi.org/10.2174/1570161053586895
DOI https://dx.doi.org/10.2174/1570161053586895 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives
Current Clinical Pharmacology Structure-Function Relationships of Iodinated Contrast Media and Risk of Nephrotoxicity
Current Medicinal Chemistry Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotective Effects of Intravenous Anesthetics: A New Critical Perspective
Current Pharmaceutical Design Some clinical applications of the electrochemical biosensors
Mini-Reviews in Medicinal Chemistry Medical Gains of Chondroitin Sulfate Upon Fucosylation
Current Medicinal Chemistry Magnesium and Anaesthesia
Current Drug Targets The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?
Current Medicinal Chemistry - Central Nervous System Agents Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View
Reviews on Recent Clinical Trials Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Synthesis, Spectral Characterization and Anticancer Activity of New 2,3,6- Substituted Quinazolin-4(3H)-one Derivatives
Letters in Organic Chemistry A Review on Emerging Drug Targets in Treatment of Schizophrenia
Current Drug Targets Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism